These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 19716866)
21. Substituted amylose matrices for oral drug delivery. Moghadam SH; Wang HW; Saddar El-Leithy E; Chebli C; Cartilier L Biomed Mater; 2007 Mar; 2(1):S71-7. PubMed ID: 18458424 [TBL] [Abstract][Full Text] [Related]
22. Report: in vitro dissolution studies of different brands of sustained release diclofenac sodium matrix tablet available in Bangladesh. Abdullah MD; Bepary S; Rouf AS Pak J Pharm Sci; 2008 Jan; 21(1):70-7. PubMed ID: 18166523 [TBL] [Abstract][Full Text] [Related]
23. A study on maize proteins as a potential new tablet excipient. Georget DM; Barker SA; Belton PS Eur J Pharm Biopharm; 2008 Jun; 69(2):718-26. PubMed ID: 18294824 [TBL] [Abstract][Full Text] [Related]
24. Preparation and characterization of pH-independent sustained release tablet containing solid dispersion granules of a poorly water-soluble drug. Tran HT; Park JB; Hong KH; Choi HG; Han HK; Lee J; Oh KT; Lee BJ Int J Pharm; 2011 Aug; 415(1-2):83-8. PubMed ID: 21641985 [TBL] [Abstract][Full Text] [Related]
25. Roles of MgO release from polyethylene glycol 6000-based solid dispersions on microenvironmental pH, enhanced dissolution and reduced gastrointestinal damage of telmisartan. Tran PH; Tran TT; Lee SA; Nho VH; Chi SC; Lee BJ Arch Pharm Res; 2011 May; 34(5):747-55. PubMed ID: 21656360 [TBL] [Abstract][Full Text] [Related]
26. Effect of preparation conditions on the nutrient release properties of alginate-whey protein granular microspheres. Chen L; Subirade M Eur J Pharm Biopharm; 2007 Mar; 65(3):354-62. PubMed ID: 17150342 [TBL] [Abstract][Full Text] [Related]
27. Carboxymethyl high amylose starch: Chitosan self-stabilized matrix for probiotic colon delivery. Calinescu C; Mateescu MA Eur J Pharm Biopharm; 2008 Oct; 70(2):582-9. PubMed ID: 18602991 [TBL] [Abstract][Full Text] [Related]
28. Cross-linked high amylose starch derivatives for drug release III. Diffusion properties. Mulhbacher J; Mateescu MA Int J Pharm; 2005 Jun; 297(1-2):22-9. PubMed ID: 15878244 [TBL] [Abstract][Full Text] [Related]
29. Study of the critical points of HPMC hydrophilic matrices for controlled drug delivery. Miranda A; Millán M; Caraballo I Int J Pharm; 2006 Mar; 311(1-2):75-81. PubMed ID: 16446063 [TBL] [Abstract][Full Text] [Related]
30. pH-sensitive polyelectrolyte complex gel microspheres composed of chitosan/sodium tripolyphosphate/dextran sulfate: swelling kinetics and drug delivery properties. Lin WC; Yu DG; Yang MC Colloids Surf B Biointerfaces; 2005 Aug; 44(2-3):143-51. PubMed ID: 16054345 [TBL] [Abstract][Full Text] [Related]
31. Drug release from starch-acetate microparticles and films with and without incorporated alpha-amylase. Tuovinen L; Peltonen S; Liikola M; Hotakainen M; Lahtela-Kakkonen M; Poso A; Järvinen K Biomaterials; 2004 Aug; 25(18):4355-62. PubMed ID: 15046926 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of sodium alginate as drug release modifier in matrix tablets. Liew CV; Chan LW; Ching AL; Heng PW Int J Pharm; 2006 Feb; 309(1-2):25-37. PubMed ID: 16364576 [TBL] [Abstract][Full Text] [Related]
33. Design and in vitro evaluation of novel sustained- release matrix tablets for lornoxicam based on the combination of hydrophilic matrix formers and basic pH-modifiers. Hamza Yel-S; Aburahma MH Pharm Dev Technol; 2010; 15(2):139-53. PubMed ID: 19895367 [TBL] [Abstract][Full Text] [Related]
34. Effects of drug solubility, drug loading, and polymer molecular weight on drug release from Polyox tablets. Kim CJ Drug Dev Ind Pharm; 1998 Jul; 24(7):645-51. PubMed ID: 9876509 [TBL] [Abstract][Full Text] [Related]
35. Crystal growth formation in melt extrudates. Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578 [TBL] [Abstract][Full Text] [Related]
36. Release mechanisms of acetaminophen from polyethylene oxide/polyethylene glycol matrix tablets utilizing magnetic resonance imaging. Tajiri T; Morita S; Sakamoto R; Suzuki M; Yamanashi S; Ozaki Y; Kitamura S Int J Pharm; 2010 Aug; 395(1-2):147-53. PubMed ID: 20580795 [TBL] [Abstract][Full Text] [Related]
37. Investigation of coated whey protein/alginate beads as sustained release dosage form in simulated gastrointestinal environment. Hébrard G; Hoffart V; Cardot JM; Subirade M; Alric M; Beyssac E Drug Dev Ind Pharm; 2009 Sep; 35(9):1103-12. PubMed ID: 19365776 [TBL] [Abstract][Full Text] [Related]
38. pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations. Riis T; Bauer-Brandl A; Wagner T; Kranz H Eur J Pharm Biopharm; 2007 Jan; 65(1):78-84. PubMed ID: 16919924 [TBL] [Abstract][Full Text] [Related]
39. Modeling a system of phosphated cross-linked high amylose for controlled drug release. Part 2: physical parameters, cross-linking degrees and drug delivery relationships. Cury BS; Castro AD; Klein SI; Evangelista RC Int J Pharm; 2009 Apr; 371(1-2):8-15. PubMed ID: 19124066 [TBL] [Abstract][Full Text] [Related]
40. Carboxymethyl Starch Excipients for Drug Chronodelivery. Ispas-Szabo P; De Koninck P; Calinescu C; Mateescu MA AAPS PharmSciTech; 2017 Jul; 18(5):1673-1682. PubMed ID: 27686941 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]